Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

d increased personal and personal related costs for our technical operations. For the year ended December 31, 2008, increased expenses resulted from investments in our development programs, increased medical education activities and increased marketing activities.

Our effective income tax rate was a benefit of 76.3 percent and an expense of 18.0 percent for the quarters ended December 31, 2008 and 2007, respectively and an expense of 22.4 percent and 29.7 percent for the year ended December 31, 2008 and 2007, respectively. Our income tax expense includes federal, state and foreign income taxes at statutory rates and the effects of various permanent differences. The decrease in the 2008 rate as compared to 2007 is primarily due to the impact of the orphan drug credit for maribavir and the decreased level of income before taxes.

Working Capital Highlights

As of December 31, 2008, ViroPharma's working capital was approximately $305.4 million, which represents a $289.0 million decrease from December 31, 2007, caused by a $366.4 million decrease in the fourth quarter of 2008 mainly related to the acquisition of Lev ($380.2 million), offset slightly by operating cash flows. Cash flow from operating activities for the three months and year ended December 31, 2008 was $0.6 million and $91.4 million, respectively.

Business Development Highlights

In October 2008, we completed our acquisition of Lev. Lev was a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The terms of the merger agreement provided for the conversion of each share of Lev common stock into upfront consideration in the aggregate amount of $442.9 million, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock, and contingent consideration (CVRs) of up
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 The report ... & by Geography - Global Trends & Forecast ... with respect to market drivers, opportunities, and trends ... tables and 27 figures spread through 217 slides ... Global Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html ...
(Date:10/25/2014)... October 23, 2014 ViaDerma, ... pharmaceutical company devoted to bringing new products to ... 2015. , ViaDerma has developed an innovative, patent-pending ... rapid mass transfer of pharmaceutical active ingredients to ... provide immediate localized therapy. The transdermal delivery method ...
(Date:10/25/2014)... 2014 BioProcess International (BPI), a ... 2014 BioProcess International Awards. The awards celebrate the ... and technology applications that will allow the industry ... global patient base. , Winners and finalists were ... very entertaining and exciting awards dinner and ceremony ...
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
Breaking Biology Technology:Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... 15, 2011 Dr. Huda Y. Zoghbi ,  director ... (NRI) at Texas Children,s Hospital and ... 2011 Neuroscience Prize of The Peter and Patricia Gruber Foundation ... mysteries behind a number of devastating neurological disorders, including Rett ...
... June 15, 2011 Palatin Technologies, Inc. (NYSE Amex: ... for sexual dysfunction indications, announced presentation and publication of ... male sexual arousal.  The underlying study was supported by ... of the New York Presbyterian Hospital and the Weill ...
... Pharma IQ is pioneering new HTA discussion platform with launch,of ... and CER Forum , which will take an innovative form ... Health Technology Assessment has recently observed an,unprecedented global  expansion. Clinical ... UK, while clinical benefit is the main focus in France ...
Cached Biology Technology:Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 2Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 3Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 4Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 5Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 6Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal 2Health Technology Assessment Goes Online 2Health Technology Assessment Goes Online 3
(Date:10/25/2014)... , Oct.  22, 2014   MedNet Solutions ... clinical study management systems, is pleased to announce the ... two-day event – to be held in ... on track to have record attendance and promises to ... The focus of the meeting is ...
(Date:10/25/2014)... 2014 This report covers the specifics of ... in heavy pursuit of research due to its versatility ... to other RNA components. miRNA,s non-coding nature and ability ... for use as a biomarker for a variety of ... diagnostics for the advancement in therapeutic development. Furthermore there ...
(Date:10/25/2014)... 2014 A recent report, "Genetic Testing Market ... and future genetic testing market. A comprehensive introduction of ... in this report. On account of our analysis of ... strengths and challenges; forecast for genetic testing has been ... grow at a CAGR of around 9% during 2013-2018. ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... Boulder, Colo., USA - Two new Geology ... the Cascade arc" and "Silica gel formation during fault ... cover everything from the discovery of fossilized whale "intestinal ... of the 2010 Eyjafjallajkull volcano eruption to new findings ...
... most basic processes -- transcription of the genetic code ... a police force that controls the flow of vehicles. ... in Nature Communications , might facilitate the development ... of disorders. Transcription indeed involves a step resembling ...
... This news release is available in German . ... diarrhoea -- these symptoms could point to an infection with ... based on a syringe-like injection apparatus called injectisome. For the ... the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, ...
Cached Biology News:Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 2Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 3Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 4Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 5Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 6Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 7Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 8Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 9Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 10Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 11Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 12Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 13Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 14Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 15Gene decoding obeys road traffic rules 23-D molecular syringes 23-D molecular syringes 3
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
Biology Products: